{"id":244994,"date":"2013-02-21T02:45:34","date_gmt":"2013-02-21T07:45:34","guid":{"rendered":"http:\/\/www.eugenesis.com\/nutrition-cluster-holds-but-dsm-profits-slide-27-as-recession-bites\/"},"modified":"2013-02-21T02:45:34","modified_gmt":"2013-02-21T07:45:34","slug":"nutrition-cluster-holds-but-dsm-profits-slide-27-as-recession-bites","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nutrition\/nutrition-cluster-holds-but-dsm-profits-slide-27-as-recession-bites.php","title":{"rendered":"Nutrition cluster holds but DSM profits slide 27% as recession bites"},"content":{"rendered":"<p><p>    Royal DSM saw 2012 EBIT (operating) profits fall 27% to 635m    from 866m in 2011  but the human and animal nutrition    business it has invested 2.4bn in since 2010 added 6% in    profit.  <\/p>\n<p>    Nutrition EBIT profits grew from 577m in 2011 to 613m in 2012    with sales up 9% to 3.667bn and boosted by the 900m Ocean    Nutrition Canada and Fortitech acquisitions in the year along    with other animal and human nutrition investments.  <\/p>\n<p>    Omega-3s and blends were singled out as star performers in the    division that includes cultures and enzymes, carotenoids,    vitamins and minerals.  <\/p>\n<p>    Board member Stephan Tanda told us the company's Martek (2011)    and ONC buys meant it could handle all omega-3 demands, even    high-end pharma requirements although the company was not    particularly active there now, preferring to focus on food and    supplements. It was however,\"keeping an eye\" on    the omega-3 drug patent landscape where blockbuster drugs were    coming off-patent.  <\/p>\n<p>    Feike Sijbesma, CEO\/chairman of the DSM managing board, praised    the nutrition division performance which he noted contributed    70% to the Dutch firms EBITDA profits of 1.1bn.  <\/p>\n<p>    The company forecast for EBITDA of 1.4bn in 2013 remained    intact despite a 'problematic Europe'that remains deep in    recession, according to Tanda.  <\/p>\n<p>    Forecasts intact  <\/p>\n<p>    You have to remember we lost about 300m in the caprolactam    nylon business in 2012. It suffered from weakness in demand so    with that excluded our 1.4bn EBITDA profit forecast for GDP    plus 2% remains intact, Tanda said.  <\/p>\n<p>    He added: Europe continues as a problem and Brazil and    latin America could be stronger, but the US market is picking    up, and China and Asia remains in growth. It is true that it is    not a pretty situation in Europe though.  <\/p>\n<p><!-- Auto Generated --><\/p>\n<p>Continued here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/www.nutraingredients-usa.com\/Industry\/Nutrition-cluster-holds-but-DSM-profits-slide-27-as-recession-bites\" title=\"Nutrition cluster holds but DSM profits slide 27% as recession bites\">Nutrition cluster holds but DSM profits slide 27% as recession bites<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> Royal DSM saw 2012 EBIT (operating) profits fall 27% to 635m from 866m in 2011 but the human and animal nutrition business it has invested 2.4bn in since 2010 added 6% in profit. Nutrition EBIT profits grew from 577m in 2011 to 613m in 2012 with sales up 9% to 3.667bn and boosted by the 900m Ocean Nutrition Canada and Fortitech acquisitions in the year along with other animal and human nutrition investments.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/nutrition\/nutrition-cluster-holds-but-dsm-profits-slide-27-as-recession-bites.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577479],"tags":[],"class_list":["post-244994","post","type-post","status-publish","format-standard","hentry","category-nutrition"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/244994"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=244994"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/244994\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=244994"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=244994"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=244994"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}